In This Section

Lung Cancer Task Force

The Lung Cancer Task Force brings together leading experts committed to advancing the field of lung cancer research. This distinguished group of thought leaders is focused on establishing both short- and long-term priorities across the entire research continuum – including basic and translational science, diagnostics, early detection, treatment, and population sciences. Through a bold, collaborative, and integrative approach, the Task Force is working to accelerate progress and improve outcomes for patients affected by lung cancer.

Chair

Charles Swanton, MBPhD

Royal Society Napier Professor
Cancer Evolution and Genome Instability Laboratory
The Francis Crick Institute and UCL Cancer Institute
London, United Kingdom

Christopher Abbosh, MD, PhD

Chief Medical Officer
SAGA Diagnostics
Lund, Sweden

Christine D. Berg, MD

Special Volunteer
Division of Cancer Epidemiology and Genetics
NIH/NCI
Bethesda, Maryland

Benjamin Besse, MD, PhD

Head of Clinical Research
Gustave Roussy
Villejuif, France

Trevor G. Bivona, MD, PhD

Professor of Medicine
University of California, San Francisco
San Francisco, California

Fiona H. Blackhall, MD, PhD

Professor of Thoracic Oncology
Honorary Consultant in Medical Oncology
The Christie NHS Foundation Trust
University of Manchester
Manchester, United Kingdom

Julie R. Brahmer, MD

Director of the Thoracic Oncology Program
Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Iona C. Cheng, PhD, MPH

Professor and Chief
Cancer Epidemiology Division
University of California, San Francisco
San Francisco, California

Dave Chuter

Patient Advocate
Cancer Grand Challenges
Bognor Regis, United Kingdom

Harry J. De Koning, MD, PhD

Deputy Head
Professor of Public Health and Screening
Erasmus University Rotterdam
Rotterdam, Netherlands

Maximilian Diehn, MD, PhD

Jack, Lulu, and Sam Wilson Professor of Radiation Oncology
Stanford University
Stanford, California

Caroline Dive, PhD

Interim Director and Director
CRUK National Biomarker Centre
CRUK Manchester Institute
Manchester, United Kingdom

Julian Downward, PhD

Principal Group Leader
Francis Crick Institute
London, United Kingdom

Susan M. Galbraith, MBBChir, PhD

(2025-2028)

Executive Vice President
AstraZeneca
Gaithersburg, Maryland

Ramaswamy Govindan, MD

Professor of Medicine
Anheuser Busch Endowed Chair in Medical Oncology
Washington University School of Medicine
St. Louis, Missouri

Alena Gros, PhD

Group Leader
Tumor Immunology and Immunotherapy
Vall d’Hebron Institute of Oncology
Barcelona, Spain

Roy S. Herbst, MD, PhD

Ensign Professor of Medicine
Deputy Director
Assistant Dean for Translational Research
Yale Cancer Center
New Haven, Connecticut

John V. Heymach, MD, PhD

Professor and Chair
Department of Thoracic/Head and Neck Medical Oncology
UT MD Anderson Cancer Center
Houston, Texas

Elizabeth M. Jaffee, MD

Deputy Director and Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Mariam Jamal-Hanjani, MD, PhD

Clinical Scientist
Department of Medical Oncology
University College London Cancer Institute
London, United Kingdom

Sam Janes, MBBS, MSc, PhD

Professor of Respiratory Medicine
University College London Cancer Institute
London, England

Pasi A. Janne, MD, PhD

Director
Lowe Center for Thoracic Oncology
Dana-Farber Cancer Institute
Boston, Massachusetts

Christopher A. Klebanoff, MD

Associate Member
Attending Physician
Laboratory Head, Human Oncology and Pathogenesis Program
Memorial Sloan Kettering Cancer Center
New York, New York

Norbert Kraut, PhD

Global Head of Cancer Research
Boehringer Ingelheim
Vienna, Austria

Se-Hoon Lee, MD, PhD

Professor
Division of Hematology/Oncology
Department of Medicine
Samsung Medical Center/Sungkyunkwan University School of Medicine
Seoul, South Korea

Christine M. Lovly, MD, PhD

Associate Professor of Medicine, Division of Hematology-Oncology
Ingram Associate Professor of Cancer Research
Co-leader, Translational Research and Interventional Oncology Program
Vanderbilt University Medical Center
Vanderbilt Ingram Cancer Center
Nashville, Tennessee

Nicholas McGranahan, PhD

Group Leader
Cancer Genome Evolution Research Group
University College London Cancer Institute
London, United Kingdom

Miriam Merad, MD, PhD

Chair, Department of Immunology and Immunotherapy
Director, Mount Sinai Human Immune Monitoring Center
Director, Marc and Jennifer Lipschultz Precision Immunology Institute
Icahn School of Medicine at Mount Sinai
New York, New York

Matthew L. Meyerson, MD, PhD

Professor of Genetics and Medicine
Dana-Farber Cancer Institute
Boston, Massachusetts

Tony S.K. Mok, MD

Associate Professor
Department of Clinical Oncology
Chinese University of Hong Kong
Hong Kong, China

Solange Peters, MD, PhD

Professor and Head of Medical Oncology
CHUV Lausanne University Hospital
Lausanne, Switzerland

Katerina A. Politi, PhD

Professor
Department of Pathology
Yale Cancer Center
New Haven, Connecticut

Sergio Quezada, PhD

Professor
Cancer Immunology and Immunotherapy
University College London Cancer Institute
London, United Kingdom

Arati V. Rao, MD

Vice President
Thoracic Oncology
Therapeutic Area Development Head
Pfizer, Inc.
New York, New York

Charles M. Rudin, MD, PhD

Deputy Director
Memorial Sloan Kettering Cancer Center
New York, New York

Kurt Schalper, MD, PhD

Associate Professor of Pathology
Director
Translational Immuno-oncology Laboratory
Yale School of Medicine
New Haven, Connecticut

Lecia V. Sequist, MD, MPH

Professor of Medicine
Harvard Medical School
Boston, Massachusetts

Alice T. Shaw, MD, PhD

Chief of Strategic Partnerships
Dana-Farber Cancer Institute
Boston, Massachusetts

Lillian L. Siu, MD

Director, Phase I Clinical Trials Program
Co-director, Robert and Maggie Bras and Family Drug Development Program
Clinical Lead, Tumor Immunotherapy Program
BMO Chair, Precision Cancer Genomics
Princess Margaret Cancer Centre
Professor of Medicine
University of Toronto
Toronto, Canada

Benjamin J. Solomon, MBBS, PhD

Consultant Medical Oncologist
Peter MacCallum Cancer Center
Melbourne, Australia

Jean-Charles Soria, MD, PhD

Senior Vice President
Oncology, Global Development
Amgen
Thousand Oaks, California

Avrum E. Spira, MD

Global Head of Interventional Oncology
Johnson & Johnson
Cambridge, Massachusetts

Brendon M. Stiles, MD

Chief
Thoracic Surgery and Surgical Oncology
Montefiore Medical Center
Bronx, New York

Daniel S.W. Tan, MBBS, PhD

Senior Consultant
Division of Medical Oncology
Head
Division of Clinical Trials and Epidemiological Sciences
Principal Investigator
Cancer Therapeutics Research Laboratory
Associate Professor
Duke-NUS Medical School
National Cancer Centre Singapore
Singapore

Jennifer S. Temel, MD

Professor of Medicine and Associate Physician
Harvard Medical School/Massachusetts General Hospital
Boston, Massachusetts

C. Jillian Tsai, MD, PhD

Lead
Allan and Ruth Kerbel Palliative Radiotherapy and Oligometastasis Program
Princess Margaret Cancer Centre
Toronto, Canada

Victor E. Velculescu, MD, PhD

Co-director of Cancer Biology
Professor of Oncology
Sidney Kimmel Comprehensive Cancer Center
Johns Hopkins University
Baltimore, Maryland

Everett E. Vokes, MD

John E. Ultmann Distinguished Service Professor of Medicine
Professor of Radiation and Cellular Oncology
Chair, Department of Medicine
Physician-in-Chief
University of Chicago Medicine and Biological Sciences
University of Chicago Medicine
Chicago, Illinois

Johnathan R. Whetstine, PhD

Professor, Jack Schultz Basic Science Endowed Chair
Director, Cancer Epigenetics Institute
Program Co-leader Nuclear Dynamics and Cancer
Director, Genomics Resource
Fox Chase Cancer Center
Philadelphia, Pennsylvania